Physical functional health and risk of future cardiovascular disease: the Scottish Health Survey.

1. Rodriguez EM, Staffa JA, Graham DJ. The role of databases in drug postmarketing surveillance. Pharmacoepidemiol Drug Saf. 2001;10(5):407-410. 2. Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. Arch Intern Med. 2005;165(12):1363-1369. 3. Moore TJ, Cohen MR, Furberg CD. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch Intern Med. 2007;167 (16):1752-1759. 4. US Food and Drug Administration. Postmarketing reporting of adverse drug experiences. Revised April 1, 2009. 21 CFR §314.80. 5. MedDRA MSSO Web site. http://www.meddramsso.com/index.asp. Accessed November 30, 2007. 6. US Food and Drug Administration. Reports received and reports entered into AERS by year. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm070434.htm. Accessed August 26, 2010. 7. Cherry DK, Woodwell DA. National ambulatory medical care survey: 2000 summary. Adv Data. 2002;(328):1-32. 8. Cherry DK, Woodwell DA, Rechtsteiner EA. National ambulatory medical care survey: 2005 summary. Adv Data. 2007;(387):1-39.